Journal of Veterinary Clinics (한국임상수의학회지)

The Korean Society of Veterinary Clinics (한국임상수의학회)
권호 표지

Evaluation for Protective Effect of CPV-2 and CPV-2b Vaccines against a Korean CPV-2a Isolate in Pups

국내에서 유행하는 CPV-2a 분리주에 대한 CPV-2와 CPV-2b 백신의 방어효능 평가

  • Jeoung, Seok-Young (Gangnam Animal Clinic) ;
  • Yi, Jun-Seok (College of Veterinary Medicine & Institute of Veterinary Science, Kangwon National University) ;
  • Kim, Hyun-Tae (College of Veterinary Medicine, Seoul National University) ;
  • Kim, Doo (College of Veterinary Medicine & Institute of Veterinary Science, Kangwon National University)
  • 정석영 (강남동물병원) ;
  • 이준석 (강원대학교 수의과대학 및 동물의학종합연구소) ;
  • 김현태 (서울대학교 수의과대학) ;
  • 김두 (강원대학교 수의과대학 및 동물의학종합연구소)
  • Accepted : 2014.07.28
  • Published : 2014.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

The aim of this study was to determine if vaccines containing CPV-2 or CPV-2b provided protection against challenge with a recent Korean CPV-2a isolate. Twenty mongrel pups aged 9 weeks old were used. The commercial CPV-2 or CPV-2b vaccines were administered to each of the 8 pups thrice every 3 weeks, respectively. Two weeks after the last vaccination, all pups were challenged with CPV-2a (VR00174 strain) $1{\times}10^6\;TCID_{50}$. Clinical signs, fecal excretion of challenged CPV, and serological response of pups were observed for 2 weeks after challenge. All vaccinated pups did not display any clinical signs of disease after challenge with Korean CPV-2a isolate, whereas all non-vaccinated pups exhibited mucoid or hemorrhagic diarrhea, vomiting and anorexia. In all non-vaccinated pups, the virus could be detected in feces from 4 days after challenge, whereas in vaccinated pups, no evidence of viral excretion could be detected. Two of 4 non-vaccinated pups died 6 days after the challenge. This study showed that the two commercial CPV-2 and CPV-2b vaccines were effective in preventing infection and/or disease caused by the Korean CPV-2a isolate.

본 연구는 상용화되어 판매되고 있는 CPV-2 백신과 CPV-2b 백신이 국내에서 주로 유행하고 있는 CPV-2a 분리주에 대해 방어능력을 가지는 지를 평가하기 위하여, CPV에 대한 예방접종을 실시하지 않은 생후 9주령의 잡종 강아지 20두를 예방접종 미실시군(대조군) 4두와 예방접종군 16두로 편성하였다. 예방접종 군의 강아지 8두씩은 3주 간격으로 3회에 걸쳐 CPV-2 또는 CPV-2b 백신을 각각 예방접종하였다. 3차 예방접종 2주 후에 모든 강아지에 $1{\times}10^6\;TCID_{50}$의 CPV-2a (VR00174 strain) 바이러스를 경구접종하였으며 강아지들의 임상증상, CPV의 변 내 배출, CPV에 대한 혈청학적 반응에 대하여 2주 동안 관찰하였다. 국내 분리 CPV-2a를 공격접종한 후에, 예방접종을 실시한 모든 강아지에서는 어떠한 임상증상도 나타나지 않았지만 예방접종을 실시하지 않은 강아지들은 식욕부진, 우둔, 구토, 점액 또는 혈액성 설사를 나타내었으며 2두는 공격접종 6일째에 폐사하였다. 예방접종을 실시하지 않은 강아지들에서는 공격접종 4일 후부터 변에서 CPV가 검출되었지만 예방접종을 실시한 강아지에서는 변에서 CPV가 검출되지 않았다. 그리고 예방접종 실시한 강아지들은 1차 예방접종에 의하여 방어수준 이상으로 CPV에 대한 항체를 형성하였다. 본 연구는 현재 국내에서 시판 중인 CPV-2와 CPV-2b 백신이 최근 국내에서 주로 분리되는 CPV-2a에 대하여 교차 방어력을 나타내는 것으로 확인되었다.

Keywords

References

  1. Appel MJG, Cooper BJ, Greisen H, Scott F, Carmichael LE. Canine viral enteritis. I. Status report on corona- and parvo-like viral enteritis. Cornell Vet 1979; 3: 123-133.
  2. Battilani M, Scagliarini A, Tisato E, Turilli C, Jacoboni I, Casadio R, Prosperi S. Analysis of canine parvovirus sequence from wolves and dogs isolated in Italy. J Gen Virol 2001; 82: 1555-1560. https://doi.org/10.1099/0022-1317-82-7-1555
  3. Carmichael LE, Joubert JC, Pollock RVH. A modified live canine parvovirus vaccine. II. Immune response. Cornell Vet 1983; 73: 13-29.
  4. Carmichael LE, Joubert JC, Pollock RVH. Hemagglutination by canine parvovirus: serologic studies and diagnostic applications. Am J Vet Res 1980; 41: 784-791.
  5. Carmichael LE, Joubert JC. A modified live canine parvovirus strain with novel plaque characteristic. I. Viral attenuation and dog response. Cornell Vet 1981; 71: 408-427.
  6. Carr-Smith S, Macintire DK, Swange LJ. Canine parvovirus. Part I. Pathogenesis and vaccination. Compend Cont Educ Pract Vet 1997; 19: 125-133.
  7. Chinchkar SR, Mohana Subramanian B, Hanumantha Rao N, Rangarajan PN, Thiagarajan D, Srinivasan VA. Analysis of VP2 gene sequences of canine parvovirus isolates in India. Arch Virol 2006; 151: 1881-1887. https://doi.org/10.1007/s00705-006-0753-8
  8. Dimmitt R. Clinical experience with cross-protective antiendotoxin antiserum in dogs with parvoviral enteritis. Canine Pract 1991; 136: 23-26.
  9. Doki M, Fujita K, Miura R, Yoneda M, Ishikawa Y, Taneno A, Kai C. Sequence analysis of VP2 gene of canine parvovirus isolated from domestic dogs in Japan in 1999 and 2000. Comp Immunol Microbiol Infect Dis 2006; 29: 199-206. https://doi.org/10.1016/j.cimid.2006.05.001
  10. Glickman LT, Domanski LM, Patronek GJ, Visintainer F. Breed-related risk factors for canine parvovirus enteritis. J Am Vet Med Assoc 1985; 187: 589-594.
  11. Greene CE. Immunoprophylaxis and immunotherapy. In: Infectious disease of dog and cat, 2nd ed. Philadelphia: WB Saunders. 1998: 723-744.
  12. Greenwood NM, Chalmers WSK, Baxendale W, Thompson H. Comparison of isolates of canine parvovirus by restriction enzyme analysis and vaccine efficacy against filed strains. Vet Rec 1995; 136: 63-67. https://doi.org/10.1136/vr.136.3.63
  13. Hirayama K, Kano R, Hosokawa-Kanai T, Tsuyama S, Nakamura Y, Sasaki Y, Hasegawa A. VP2 gene of a canine parvovirus isolate from stool of a puppy. J Med Vet Sci 2005; 67: 139-143. https://doi.org/10.1292/jvms.67.139
  14. Huston DM, Ribble CS, Head LL. Risk factors associated with parvovirus enteritis in dogs: 283 cases (1982-1991). J Am Vet Med Assoc 1996; 208: 542-546.
  15. Ikeda Y, Mochizuki M, Naito R, Nakamura K, Miyazawa T, Mikami T, Takahashi E. Predominance of canine parvovirus (CPV) in unvaccinated cat populations and emergence of new antigenic types of CPVs in cats. Virology 2000; 278: 13-19. https://doi.org/10.1006/viro.2000.0653
  16. Jeoung SY, Ahn SJ. Kim D. Genetic analysis of VP2 gene of canine parvovirus isolates in Korea. J Vet Med Sci 2008; 70: 719-722. https://doi.org/10.1292/jvms.70.719
  17. Larson LJ, Schultz RD. Do tow current canine parvovirus type 2 and 2b vaccines provide protection against the now type 2c variant? Vet Ther 9; 94-101, 2008.
  18. Macintire DK, Smith-Carr S. Canine Parvovirus. Part II. Clinical Signs, Diagnosis, and Treatment. Compend Cont Educ Pract Vet 1997; 19: 291-300.
  19. Mann FA, Boon GD, Wagner-Mann CC, Ruben DS, Harrington DP. Ionized and total magnesium concentrations in blood from dogs with naturally acquired parvoviral enteritis. J Am Vet Med Assoc 1998; 212: 1398-1401.
  20. Martella V, Cavalli A, Pratelli A, Bozzo G, Camero M, Buonavoglia D, Narcisi D, Tempesta M, Buonavoglia C. A canine parvovirus mutant is spreading in Italy. J Clin Microbiol 2004; 42: 1333-1336. https://doi.org/10.1128/JCM.42.3.1333-1336.2004
  21. Mochizuki M, Harasawa R, Nakatami H. Antigenic and genomic variabilities among recently prevalent parvoviruses of canine and feline origin in Japan. Vet Microbiol 1993; 38: 1-10. https://doi.org/10.1016/0378-1135(93)90070-N
  22. Spibey N, Greenwood NM, Sutton D, Chalmers WS, Tarpey I. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Vet Microbiol 2008; 128: 48-55. https://doi.org/10.1016/j.vetmic.2007.09.015
  23. Truyen U, Platzer G, Parrish CR. Antigenic type distribution among canine parvoviruses in dogs and cats in Germany. Vet Rec 1996; 138: 365-366. https://doi.org/10.1136/vr.138.15.365
  24. Truyen U. Emergence and recent evolution of canine parvovirus. Vet Microbiol 1999; 69: 47-50. https://doi.org/10.1016/S0378-1135(99)00086-3